Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2024)
Immix Biopharma (IMMX) reported Total Non-Current Liabilities of $9.7 million for Q4 2024, up 160.54% on a YoY basis from $3.7 million in Q1 2024, and up 27.74% sequentially from $7.6 million in Q3 2024.
Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Immix Biopharma (IMMX) has 5 years of Total Non-Current Liabilities data on file, last reported at $9.7 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 160.54% year-over-year to $9.7 million; the trailing twelve-month figure through Dec 2024 stood at $9.7 million (up 160.54% YoY), and the FY2024 full-year result was $9.7 million, up 160.54% from the prior year.
- Total Non-Current Liabilities improved to $9.7 million in Q4 2024, from $7.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.7 million in Q4 2024 to a low of -$23.2 million in Q4 2021.
- A 5-year average of $2.0 million and a median of $4.8 million in 2020 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 594.4% in 2021 and surged 160.54% in 2024, its largest moves.
- Tracing IMMX's Total Non-Current Liabilities over 5 years: stood at $4.7 million in 2020, then sank by 594.4% to -$23.2 million in 2021, then surged by 107.53% to $1.7 million in 2022, then soared by 112.88% to $3.7 million in 2023, then surged by 160.54% to $9.7 million in 2024.
- Business Quant data shows IMMX's Total Non-Current Liabilities at $9.7 million in Q4 2024, $7.6 million in Q3 2024, and $4.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.70 Mn |
| Sep 30, 2024 | 7.59 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | -23.21 Mn |
| Dec 31, 2020 | 4.70 Mn |